Hyperglycemia is associated with greater hematoma expansion and poor clinical outcomes after intracerebral hemorrhage. We show that cerebral hematoma expansion triggered by intracerebral infusion of autologous blood is greater in diabetic rats and mice compared to nondiabetic controls and that this augmented expansion is ameliorated by plasma kallikrein (PK) inhibition or deficiency. Intracerebral injection of purified PK augmented hematoma expansion in both diabetic and acutely hyperglycemic rats, whereas injection of bradykinin, plasmin or tissue plasminogen activator did not elicit such a response. This response, which occurs rapidly, was prevented by co-injection of the glycoprotein VI agonist convulxin and was mimicked by glycoprotein VI inhibition or deficiency, implicating an effect of PK on inhibiting platelet aggregation. We show that PK inhibits collagen-induced platelet aggregation by binding collagen, a response enhanced by elevated glucose concentrations. The effect of hyperglycemia on hematoma expansion and PK-mediated inhibition of platelet aggregation could be mimicked by infusing mannitol. These findings suggest that hyperglycemia auguments cerebral hematoma expansion by PK-mediated osmotic-sensitive inhibition of hemostasis.
Intracerebral hemorrhage (ICH) accounts for 7-20% of all cases of stroke, with an overall fatality rate within 1 month of 42% (ref. 1) . Both diabetes and admission hyperglycemia are independently associated with early and long-term mortality after ICH [2] [3] [4] [5] . In addition, hyperglycemia is independently associated with symptomatic ICH in stroke patients treated with intravenous tissue plasminogen activator 6, 7 . Hematoma volume is an independent determinant of both mortality and poor outcome after ICH 8, 9 . Hyperglycemia is associated with greater hematoma volume and expansion 3, [10] [11] [12] [13] [14] ; however, the role of hyperglycemia in contributing to hematoma expansion and regulating cerebral hemostasis after vascular injury is not fully understood. Moreover, although more than 50% of individuals with stroke have hyperglycemia 15 , the clinical benefit of glucose normalization in the setting of acute stroke is controversial 16, 17 . Data on the clinical benefit of glucose lowering in ICH are limited, and the potential therapeutic window for glucose lowering is unknown 4, 18, 19 . Recent guidelines suggest a conservative approach to the management of hyperglycemia in individuals with spontaneous ICH until additional clinical information is available 20 . Here we have investigated the effect of diabetes and hyperglycemia on acute hematoma expansion and the mechanisms that may contribute to hematoma expansion after experimental ICH.
We first compared the response to intracerebral infusion of autologous whole blood in rats with 4 weeks of streptozotocin-induced diabetes with age-matched nondiabetic rats. This procedure allowed us to quantify the effect of diabetes on hemorrhagic response independently of other variables associated with the incidence and severity of ICH. Hematoma expansion to the subarachnoid space in diabetic rats infused with autologous blood was tenfold greater than that observed in nondiabetic rats (Fig. 1a,b) . The contralateral cerebral hemisphere was injected with PBS and showed a smaller magnitude of hematoma expansion than did the hemisphere injected with blood, and there was a trend toward greater hematoma expansion in diabetic compared with nondiabetic rats (Fig. 1a,b) . Infusion of autologous blood labeled with Evans blue dye showed that the blood remained localized to the site of injection. The hematoma observed within 30 min on the surface of the brain in diabetic rats was not labeled, indicating that the rapid appearance of blood in the subarachnoid space was probably derived from vessels ruptured during needle insertion (Supplementary Fig. 1 ). As in the streptozotocin-induced diabetic rats, hematoma expansion was greater in diabetic Akita mice (C57BL/6J-Ins2 Akita ) subjected to autologous blood injection than in nondiabetic littermate controls (Fig. 1c) .
Previously, we implicated PK in blood-brain barrier dysfunction after experimental ICH 21 . PK is activated from plasma prekallikrein (PPK) by coagulation factor XII through the contact activation system and has a central role in the intrinsic coagulation cascade, innate inflammation, vascular function and fibrinolysis 22 . We therefore investigated the potential role of PK in hematoma expansion in diabetic animals. Systemic administration of the small-molecule PK inhibitor ASP-440 (ref. 23 ) attenuated hematoma expansion in diabetic rats (Fig. 1d) . ASP-440-treated diabetic rats receiving a sham injection of PBS in the contralateral hemisphere also showed a smaller magnitude of hematoma expansion than did vehicle-treated rats receiving the same injection (Fig. 1d) . In addition, in diabetic rats, co-injection of blood with a neutralizing PK-specific antibody significantly attenuated hematoma expansion compared with the contralateral hemisphere co-injected with blood and control IgG (Fig. 1e) .
To further characterize the role of PK in hematoma expansion, we obtained mice homozygous for a knockout allele of the gene encoding PPK, Klkb1, and lacking PPK expression ( Supplementary  Fig. 2 ). Hematoma volume was significantly smaller in streptozotocininduced diabetic Klkb1 −/− mice subjected to autologous blood injection than in diabetic wild-type mice (Fig. 1f,g ). Klkb1 −/− mice showed prolonged activated partial thromboplastin time (aPTT) (Fig. 1h) , which is a measure of the integrity of the intrinsic coagulation cascade. The prolongation of aPTT is also seen in PK deficiency in humans 24, 25 . In diabetic rats, both aPTT and tail bleeding time were shorter than in nondiabetic controls (Supplementary Fig. 3a,b) . Shortened aPTT has also been reported in individuals with impaired fasting plasma glucose and diabetes 26 . Both aPTT and tail bleeding time were prolonged in diabetic rats by treatment with ASP-440 ( Supplementary Fig. 3a,b) , although ASP-440 attenuated blood-induced hematoma expansion (Fig. 1d) . These findings demonstrate an inverse correlation of aPTT and hematoma expansion during experimental ICH in hyperglycemic animals, suggesting that activation of PK in the intrinsic pathway promotes hematoma expansion in hyperglycemia.
To confirm the effect of PK in mediating the augmented cerebral hematoma expansion in diabetic rats, we performed intracerebral injection of purified PK and show that hematoma expansion to the subarachnoid space induced by PK was ninefold greater in diabetic rats than in nondiabetic controls (Fig. 2a,b) . Moreover, in rats injected with PK, hemorrhage volume, as assessed by erythrocyte components hemoglobin (Fig. 2c) and carbonic anhydrase-1 (Fig. 2d) in a 5-mm coronal section of the hemisphere encompassing the injection site, was two-to fourfold greater in diabetic rats than in nondiabetic rats. PK-induced hematoma expansion in diabetic rats was rapid, occurring within 30 min (Fig. 2e) , comparable to the response to autologous blood injection (Supplementary Fig. 1 ). We next examined whether hyperglycemia was required for PK-induced hematoma expansion. Rats with 4 weeks of streptozotocin-induced diabetes were injected with insulin to lower blood glucose from 428 ± 35 mg dl −1 to 158 ± 19 mg dl −1 ( Supplementary  Fig. 4 ) immediately before intracerebral injection of PK. Analysis of hematoma expansion 2 h after infusion showed that normalization of blood glucose in diabetic rats prevented PK-induced cerebral hematoma expansion (Fig. 2f) . We also examined the effect of hyperglycemia on cerebral hematoma expansion in nondiabetic rats subjected to an intraperitoneal injection of glucose (3 g per kg body weight) that resulted in a blood glucose increase from 91.4 ± 6.7 mg dl −1 at baseline to 443 ± 15 mg dl −1 30 min after injection (Fig. 2g) . Hematoma expansion after intracerebral PK injection was greater in hyperglycemic rats than in control rats (Fig. 2h) . These observations indicate that hyperglycemia per se is necessary and sufficient for facilitating hematoma expansion.
Acute hypertension, a local coagulation deficit, or both may be associated with hematoma expansion 27 . Although both heart rate and blood pressure rose after intracerebral PK injection, these effects were similar in the nondiabetic and diabetic groups ( Supplementary Fig. 5 ), suggesting that elevated blood pressure does not explain the greater magnitude of hematoma expansion in diabetic rats. PK activates various substrates, including factor XII, high-molecular weight kininogen, prourokinase and plasminogen 28 . One of the most intensively characterized functions of PK is as an enzyme that proteolytically cleaves high-molecular weight kininogen, leading to the production of bradykinin, which causes vascular dilation and permeability via the bradykinin-1 and bradykinin-2 receptors (B1R and B2R). To test whether bradykinin production is responsible for the effect of PK in promoting hematoma expansion, we performed studies on inhibiting bradykinin receptors and found that systemic or local administration of the B1R and B2R antagonists [des-Arg 10 ]-Hoe140 and Hoe140, respectively, did not attenuate bloodinduced hematoma expansion in diabetic rats, although we observed a nonsignificant trend toward a small decrease in hematoma expansion with Hoe140 administration (Fig. 1d and Supplementary Fig. 6a ). 
Hemoglobin (mg dl Intracerebral injection of bradykinin caused a nonsignificant trend toward increasing hematoma expansion in both normoglycemic and hyperglycemic rats, but hyperglycemia did not increase this response to bradykinin administration (Supplementary Fig. 6b ). These results indicate that bradykinin does not mediate the effect of hyperglycemia in augmenting blood-induced hematoma expansion. We next examined the potential effect of PK-mediated plasminogen activation on hematoma expansion. Whereas PK is capable of cleaving plasminogen to plasmin, this cleavage was not affected by glucose (Supplementary Fig. 7a,b) . Plasminogen activation by PK may affect blood clot formation and fibrinolysis, leading to hematoma expansion; however, continuous assays of clot formation and fibrinolysis showed that PK did not inhibit thrombin-induced clot formation or fibrinolysis ( Supplementary Fig. 7c,d) . In vivo, infusion of neither tissue plasminogen activator nor plasmin induced hematoma expansion in diabetic rats as observed with infusion of PK (Supplementary Fig. 7e ). To further evaluate the role of PK catalytic activity in hematoma expansion, we deactivated PK by incubating it with 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (Supplementary Fig. 8a ). Intracerebral injection of deactivated PK induced hematoma expansion in diabetic rats similar to active PK (Fig. 2i) . Moreover, high concentrations of glucose did not elevate PK's enzymatic activity ( Supplementary  Fig. 8b ). These results suggest that the effect of PK in augmenting hematoma expansion in hyperglycemia does not involve its previously characterized effects on the plasminogen systems.
Platelet aggregation is a key mechanism for normal hemostasis, limiting blood loss after hemorrhage 29 . Prior antiplatelet therapy is associated with greater hematoma volume and hematoma expansion 13, 30 . Although platelet biology differs between humans and rodents, analysis of platelets in experimental rodent models has provided insight into hemostasis and platelet aggregation in humans 31 . We found that PK inhibited collagen-stimulated platelet aggregation in a dose-dependent manner from 150 to 500 nM ( Fig. 3a) but had no effect on ADP-or thrombininduced platelet aggregation (Fig. 3b) . Glucose (5-25 mM) enhanced the inhibitory effect of PK on collagen-stimulated platelet aggregation in a dose-dependent manner (Fig. 3c) , although glucose did not alter platelet aggregation in the absence of PK (data not shown). PK exerted a similar effect on collagen-stimulated aggregation of washed platelets from both nondiabetic and diabetic rats (Supplementary Fig. 8c ). Similar to active PK, deactivated PK also inhibited collagen-stimulated platelet aggregation, whereas PPK was not inhibitory (Fig. 3d) . ASP-440 did not inhibit the effect of PK on collagen-induced platelet aggregation (Supplementary Fig. 8d ), although the concentration of ASP-440 used was sufficient to completely inhibit the catalytic activity of PK (Supplementary Fig. 8e ). These findings suggest that activation of PPK to PK is required to inhibit collagen-induced platelet activation but that, once PK is formed, its proteolytic activity is no longer required. These findings also suggest that the effect of ASP-440 in reducing hematoma expansion is due to a requirement for PK catalytic activity in generating PK from PPK in the blood at the site of cerebrovascular hemorrhage via the activation of contact system.
Platelets interact with subendothelial collagen in damaged blood vessels by means of several molecules, including glycoprotein Ib, glycoprotein VI (GPVI) and α2β1 integrin. GPVI has a crucial role in initiating downstream platelet activation 29, 32, 33 . Humans with GPVI defects are usually described as having a mild bleeding disorder, and their platelets show severely impaired responses to collagen 34 . To determine the role of GPVI in hematoma expansion after cerebral vascular injury, we examined the effect of intracerebral injection of the GPVI-blocking monoclonal antibody JAQ1 and the effect of GPVI deficiency resulting from FcR γ-chain gene disruption 35 on hematoma expansion in mice. Both local inhibition of GPVI by injection of JAQ1 in the brain and systemic GPVI deficiency resulted in greater hematoma volume and area compared with mice injected with control IgG or with wild-type mice, respectively (Fig. 3e,f) . Collagen-related peptide (CRP), which mimics the collagen triple helix, activates platelets by binding specifically to GPVI 32 , whereas snake venom convulxin activates platelet GPVI through a mechanism independent of its collagen binding site 36 . When infused together with PK into diabetic rats, convulxin (35 ng) prevented hematoma expansion (Fig. 3g) , indicating that increased local activation of GPVI can interfere with PK's hemorrhagic effect. PK inhibited CRP-induced (100 ng ml −1 ) but not convulxin-induced (0.25 nM) platelet aggregation (Fig. 3h) ; however, the inhibitory effect of PK on CRP-induced platelet aggregation was not affected by glucose (Fig. 3h) , suggesting that the collagen-binding site on GPVI is required for PK's effect on platelet aggregation and that the response to elevated glucose concentrations is mediated by collagen. Although these findings suggest a role for GPVI in PK-induced hematoma expansion, PK may also interfere with other mechanisms of platelet-collagen interaction. We observed dose-dependent binding of PK (0.3-1 µM) to collagen by surface plasmon resonance spectroscopy (Fig. 4a) . This specific binding increased in the presence of 25 mM glucose (Fig. 4b) . Ex vivo studies confirmed this finding: in rat aorta from which the endothelium was scraped to expose the underlying basement membrane, the binding of PK to aorta increased with increasing concentrations of glucose (Fig. 4c) . These results suggest that a high concentration of glucose increases PK binding to collagen, thereby enhancing PK inhibition of collagen-induced platelet aggregation. Although the mechanism by which glucose increases the binding of collagen to PK remains unclear, previous reports have suggested that a short period of hyperglycemia may alter collagen conformation and facilitate protein binding 37 .
The effect of acute hyperglycemia on hematoma expansion in nondiabetic rats (Fig. 2h) suggested that hyperosmolality might contribute to the effects of high glucose in our ICH model. Similar to the effects of high glucose, both hyperosmolar mannitol (25 mM) and hyperosmolar salt (12.5 mM) (328 mOsm l −1 ) augmented PK's inhibitory effect on collageninduced platelet aggregation compared to buffer with normal osmolarity (303 mOsm l −1 ), which is comparable to the osmolality of serum (280-303 mOsm per kg body weight) (Fig. 4d) . Nondiabetic rats treated intravenously with 20% mannitol showed similar extents of hematoma expansion 2 h after PK or blood injection (Fig. 4e,f) as compared to diabetic rats subjected to PK (Fig. 2e) or blood injection ( Supplementary  Fig. 6a ). These results suggest that hematoma expansion associated with hyperglycemia is mediated by its accompanying increase in osmolality, consistent with a report that elevated plasma osmolality on admission is associated with stroke mortality 38 . Mannitol has been used to reduce intracerebral pressure and edema in individuals with stroke, but its effect on hematoma expansion during ICH has not been reported. Our findings suggest that providing mannitol during active ICH may interfere with collagen-stimulated platelet aggregation.
Here we have shown that hyperglycemia increases the magnitude of hematoma expansion during experimental ICH and that this effect is mediated by PK. An osmotic-sensitive mechanism for PK inhibition of collagen-induced platelet aggregation, which to our knowledge has not been previously described, could contribute to impaired hemostasis in this setting. We suggest that PK represents a target for interfering with hematoma expansion under conditions of hyperglycemia. The main limitations of our experimental ICH model are that the initiating event causing cerebrovascular injury does not emulate the etiology of spontaneous ICHs in humans 39 and that responses in rodent models, particularly using otherwise healthy animals, cannot fully mimic vasculopathies and hemostatic events in individuals with ICH. Given the challenges inherent in modeling hemorrhage in animal models, more studies will be needed to determine the role of PK in ICH during hyperglycemia in the clinical setting.
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